<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124249">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01735773</url>
  </required_header>
  <id_info>
    <org_study_id>HEPCIDIN-HASEKI</org_study_id>
    <nct_id>NCT01735773</nct_id>
  </id_info>
  <brief_title>Role of Prohepcidin in Uremic Patients</brief_title>
  <official_title>The Relationship of Prohepcidin Levels With Anemia and Inflammatory Markers in Non-diabetic Uremic Patients: A Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haseki Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haseki Training and Research Hospital</source>
  <oversight_info>
    <authority>Turkey: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aimed to study the effect of prohepcidin levels on hematologic parameters
      and inflammatory markers in non-diabetic uremic patients. The investigators selected three
      groups of patients: Hemodialysis group, peritoneal dialysis group and the group with stage 4
      chronic kidney disease. A control group was formed from healthy volunteers also. Each group
      has been planned to be formed of about 25 patients. Diabetic patients were excluded.
      Prohepcidin, hsCRP, IL-6, fibrinogen have been planned to be studied besides other routine
      biochemical analysis including hematological ones.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>prohepcidin level</measure>
    <time_frame>Six months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Prohepcidin levels will be compared with other inflammatory markers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anemia and inflammatory markers</measure>
    <time_frame>Six months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Correlations of prohepcidin levels with anemia and inflamatory markers</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">25</enrollment>
  <condition>Inflammation</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Hemodialysis group</arm_group_label>
    <description>Patients on chronic hemodialysis program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peritoneal dialysis group</arm_group_label>
    <description>Patients on chronic peritoneal dialysis program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-dialysis group</arm_group_label>
    <description>Patients with chronic kidney disease stage-4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Healthy volunteers</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        We selected three groups of patients: Hemodialysis group, peritoneal dialysis group and
        the group with stage 4 chronic kidney disease. A control group was formed from healthy
        volunteers also.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hemodialysis and peritoneal dialysis patients who had been on dialysis therapy for
             more than 3 months,

          -  age between 18-80 years,

          -  patients with creatinine clearance between 15-30 ml/min.

        Exclusion Criteria:

          -  age less than 18 or more than 80,

          -  diabetic patients,

          -  current active infectious or inflammatory disease.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Haseki Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34390</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 27, 2012</lastchanged_date>
  <firstreceived_date>November 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>inflammation</keyword>
  <keyword>iron</keyword>
  <keyword>peritoneal dialysis</keyword>
  <keyword>prohepcidin</keyword>
  <keyword>uremia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
